Related Experiment Video
Updated: Jun 29, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Antiangiogenic therapy in malignant gliomas
Andrew D Norden1, Jan Drappatz, Patrick Y Wen
1Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. anorden@partners.org
Current Opinion in Oncology
|October 9, 2008
Summary
Antiangiogenic drugs, like bevacizumab, show effectiveness in treating recurrent malignant gliomas. Further research is exploring their role in first-line therapy and overcoming resistance to improve patient survival.
Area of Science:
- Oncology
- Neuro-oncology
- Cancer Therapy
Background:
- Malignant gliomas are aggressive brain tumors.
- Angiogenesis plays a critical role in glioma growth and progression.
- Targeting tumor angiogenesis is a key therapeutic strategy.
Purpose of the Study:
- To review the rationale for antiangiogenic therapy in malignant gliomas.
- To summarize clinical trial outcomes of antiangiogenic drugs.
- To discuss future directions in this therapeutic area.
Main Methods:
- Review of current literature on antiangiogenic agents in malignant glioma.
- Analysis of clinical trial data for drugs targeting angiogenesis.
- Discussion of emerging therapeutic strategies and resistance mechanisms.
Main Results:
- Combination therapy with bevacizumab (a monoclonal antibody against vascular endothelial growth factor) and irinotecan is a preferred treatment for recurrent malignant gliomas.
- This combination significantly improves progression-free survival compared to historical data.
- Small molecule inhibitors targeting vascular endothelial growth factor receptors are under investigation and show potential.
Conclusions:
- Antiangiogenic therapies are effective and well-tolerated for recurrent malignant gliomas.
- The role of these agents in first-line therapy requires further investigation.
- Ongoing studies aim to understand and overcome resistance mechanisms to enhance survival in patients with malignant gliomas.
